Treatment of Hepatitis C With the Earliest Protease Inhibitor-Based Therapy

被引：0
|
作者：
Smith, Zohreh Movahedi [1 ]
Brussman, Keith [1 ]
Nadir, Abdul [1 ]
机构：
[1] Maricopa Cty Gen Hosp, Phoenix, AZ 85008 USA
来源：
MAYO CLINIC PROCEEDINGS | 2014年 / 89卷 / 09期
关键词：
TRIPLE THERAPY; GENOTYPE;
D O I：
10.1016/j.mayocp.2014.06.020
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1319 / 1320
页数：3
相关论文
共 50 条
  • [21] Protease inhibitor-based triple therapy is highly effective in liver transplant recipients with genotype 1 hepatitis C recurrence: A Canadian multicentre experience
    Faisal, Nabiha
    Renner, Eberhard L.
    Bilodeau, Marc
    Yoshida, Eric M.
    Wong, Philip
    Ma, Mang M.
    Burak, Kelly W.
    Al-Judaibi, Bandar
    Cooper, Curtis
    Shaw-Stiffel, Thomas
    Lilly, Les
    HEPATOLOGY, 2013, 58 : 238A - 238A
  • [22] Immune reconstitution after successful treatment with protease inhibitor-based and protease inhibitor-sparing antiretroviral regimens
    Smith, KY
    Steffens, CM
    Truckenbrod, A
    Landay, A
    Al-Harthi, L
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 29 (05) : 544 - 545
  • [23] Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection
    Gentile, Ivan
    Buonomo, Antonio Riccardo
    Zappulo, Emanuela
    Minei, Giuseppina
    Morisco, Filomena
    Borrelli, Francesco
    Coppola, Nicola
    Borgia, Guglielmo
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 493 - 504
  • [24] Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C
    Foote, Bryce S.
    Spooner, Linda M.
    Belliveau, Paul P.
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (09) : 1085 - 1093
  • [25] Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy
    Clough, LA
    D'Agata, E
    Raffanti, S
    Haas, DW
    CLINICAL INFECTIOUS DISEASES, 1999, 29 (01) : 75 - 81
  • [26] The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy
    Becker, SL
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (03) : 401 - 412
  • [27] Detectability of HIV Residual Viremia despite Therapy Is Highly Associated with Treatment with a Protease Inhibitor-Based Combination Antiretroviral Therapy
    Darcis, Gilles
    Maes, Nathalie
    Pasternak, Alexander O.
    Sauvage, Anne-Sophie
    Frippiat, Frederic
    Meuris, Christelle
    Uurlings, Francoise
    Lecomte, Marianne
    Leonard, Philippe
    Elmoussaoui, Majdouline
    Fombellida, Karine
    Vaira, Dolores
    Moutschen, Michel
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [28] Immunologic response to protease inhibitor-based highly active Antiretroviral therapy: A review
    Wainberg, Mark A.
    Clotet, Bonaventura
    AIDS PATIENT CARE AND STDS, 2007, 21 (09) : 609 - 620
  • [29] Protease inhibitor-based antiretroviral therapy in pregnancy: effects on hormones, placenta, and decidua
    Dunk, Caroline E.
    Serghides, Lena
    LANCET HIV, 2022, 9 (02): : E120 - E129
  • [30] First generation protease inhibitor-based triple therapy and risk of hepatocellular carcinoma
    Fenkel, Jonathan M.
    Francis, Gloria
    Chan, Doris H.
    Halegoua-De Marzio, Dina
    Sass, David A.
    Herrine, Steven K.
    Civan, Jesse M.
    HEPATOLOGY, 2014, 60 : 847A - 847A
12345